



26 August 2021

## Launch: Testosterone Topical Solution USP, 30mg per actuation

**Melbourne, Australia; 26 August 2021:** Acrux Limited (ASX:ACR, “Acrux” or the “Company”) is pleased to announce that its licensee, Dash Pharmaceuticals, has commenced marketing and has product available in the United States for the Company’s generic Testosterone Topical Solution USP, 30mg per actuation.

### Background

- Acrux licensed the topical product to Dash Pharmaceuticals in October 2020
- The Abbreviated New Drug Application (ANDA) for the product was approved by the FDA earlier in 2021
- The addressable market for the product is US\$20 million per year and there are 4 marketed generics<sup>1</sup>

#### **Acrux CEO and Managing Director, Michael Kotsanis said:**

*“This is the first of the pipeline of topical generic products that Acrux has launched. It’s an important milestone for the company. We look forward to further announcements in coming months about product submissions to the FDA and subsequent launches as our pipeline matures.”*

Authorised by the Board of Acrux Limited.

#### **For more information, please contact:**

**Michael Kotsanis**  
**Acrux Limited**  
**CEO & Managing Director**  
P: + 61 3 8379 0100  
E: michael.kotsanis@acrux.com.au

### About Acrux

Acrux (ASX: ACR) is a pharmaceutical company dedicated to developing and commercialising topical pharmaceuticals. Incorporated in 1998 and using in house facilities and capabilities, Acrux has successfully developed and commercialised through licensees a number of topically applied pharmaceutical products in the US and Europe. Acrux is developing of a range of generic products for the US market by leveraging its on-site laboratories, GMP manufacturing suite, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss partnering and product development.

For further information on Acrux, visit [www.acrux.com.au](http://www.acrux.com.au)

---

<sup>1</sup> Twelve months sales to end June 2021 based on IQVIA sales data.